Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NRAS G12D”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05585320
What this trial is testing

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorPancreatic AdenocarcinomaMalignant Melanoma (Cutaneous)+1 more
Immuneering Corporation 209
Testing effectiveness (Phase 2)Ended earlyNCT03745326
What this trial is testing

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Who this might be right for
Gastrointestinal CancerPancreatic CancerGastric Cancer+2 more
National Cancer Institute (NCI) 5
Early research (Phase 1)Not Yet RecruitingNCT07014878
What this trial is testing

DCTY1102 Injection in Participants With Advanced Solid Tumors

Who this might be right for
Colorectal CancerLung CancerPancreatic Cancer
Beijing DCTY Biotech Co.,Ltd. 18
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Early research (Phase 1)Study completedNCT04853017
What this trial is testing

ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Who this might be right for
Minimal Residual DiseaseKRAS G12DKRAS G12R+9 more
Elicio Therapeutics 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT05726864
What this trial is testing

ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaColorectal CancerKRAS G12D+11 more
Elicio Therapeutics 158
Not applicableAvailableNCT07083479
What this trial is testing

Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma

Who this might be right for
Pancreatic Ductal AdenocarcinomaKRAS G12DKRAS G12V+12 more
Elicio Therapeutics
Testing effectiveness (Phase 2)Looking for participantsNCT06162221
What this trial is testing

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Who this might be right for
Non-Small Cell Lung Cancer, NSCLCKRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc. 616
Early research (Phase 1)Looking for participantsNCT07584226
What this trial is testing

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

Who this might be right for
Advanced NRAS-Mutant MelanomaAdvanced NRAS-Mutant Solid TumorsNRAS Mutation+8 more
Relay Therapeutics, Inc. 35
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30